Sean Ross
Research Triangle Park
6 Papers
135 Citations
Sean Ross is an academic researcher from Research Triangle Park. The author has contributed to research in topics: Agonist & GPR120. The author has an hindex of 6, co-authored 6 publications.
Chat about Author
Papers
Inhibition of apical sodium-dependent bile acid transporter as a novel treatment for diabetes.
Lihong Chen,Xiaozhou Yao,Andrew J. Young,Judi A. McNulty,Donald W. Anderson,Yaping Liu,Christopher Nystrom,Dallas K. Croom,Sean Ross,Jon L. Collins,Deepak K. Rajpal,Kimberly Hamlet,Chari D. Smith,Bronislava Gedulin +13 more
TL;DR: It is demonstrated that inhibition of Asbt increases bile acids in the distal intestine, promotes Glp-1 release and may offer a new therapeutic strategy for type 2 diabetes mellitus.
106
Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120)
Steven M. Sparks,Grace Chen,Jon L. Collins,Dana P. Danger,Dock Steven Thomas,Channa K Jayawickreme,Stephen Jenkinson,Christopher P. Laudeman,M. Anthony Leesnitzer,Xi Liang,Patrick R. Maloney,David C McCoy,David Moncol,Vincent Rash,Thomas J. Rimele,Padmaja Vulimiri,James M. Way,Sean Ross +17 more
TL;DR: The exploration of a diarylsulfonamide series of free fatty acid receptor 4 (FFA4/GPR120) agonists is described, which led to the identification of selective FFA4 agonist 8 (GSK137647A) and selective F FA4 antagonist 39.
104
Predicting QT prolongation in humans during early drug development using hERG inhibition and an anaesthetized guinea-pig model
Xiaozhou Yao,Don L. Anderson,Sean Ross,Daniel G. Lang,B Z Desai,D C Cooper,Pat Wheelan,Maggie S. McIntyre,M L Bergquist,K I MacKenzie,J D Becherer,Mir Hashim +11 more
TL;DR: The purpose of the present study was to develop and verify a reliable and relatively simple approach for assessing, during preclinical development, the propensity of drugs to prolong the QT interval in humans.
80
Exploration of phenylpropanoic acids as agonists of the free fatty acid receptor 4 (FFA4): Identification of an orally efficacious FFA4 agonist.
Steven M. Sparks,Christopher Joseph Aquino,Pierette Banker,Jon L. Collins,David J. Cowan,Caroline J. Diaz,Dock Steven Thomas,Donald L. Hertzog,Xi Liang,Erin Swiger,Josephine Yuen,Grace Chen,Channa K Jayawickreme,David Moncol,Christopher Nystrom,Vincent Rash,Thomas J. Rimele,Shane Roller,Sean Ross +18 more
TL;DR: Work to identify agonists with appropriate pharmacokinetic properties to support progression into in vivo studies led to the identification of compound 29, a FFA4 agonist which lowers plasma glucose in two preclinical models of type 2 diabetes.
20
Discovery of 6,7-Dihydro-5H-pyrrolo[2,3-a]pyrimidines as Orally Available G Protein-Coupled Receptor 119 Agonists
Subba Reddy Katamreddy,Andrew J. Carpenter,Carina Ammala,Eric E. Boros,Ronald L. Brashear,Celia P. Briscoe,Sarah R. Bullard,Richard Dana Caldwell,Christopher R. Conlee,Dallas K. Croom,Shane M. Hart,Dennis Heyer,Paul R. Johnson,Jennifer A. Kashatus,Doug Minick,Peckham Gregory,Sean Ross,Shane Roller,Vicente Samano,Howard Ray Sauls,Sarva M. Tadepalli,James B. Thompson,Yun Xu,James M. Way +23 more
TL;DR: Compound 3 appeared to modulate the enteroinsular axis, improve glycemic control, and strengthen previous suggestions that GPR119 agonists may have utility in the treatment of type 2 diabetes.
20